Cargando…

Connexin 43 is an independent predictor of patient outcome in breast cancer patients

PURPOSE: Gap junctions are specialized membrane structures that form channels between adjacent cells allowing cell communication. Gap junctions and specifically Connexin 43 (Cx43) are down-regulated in cancer; however, there are contrasting reports on how this effects breast cancer patient survival....

Descripción completa

Detalles Bibliográficos
Autores principales:	Chasampalioti, Maria, Green, Andrew R., Ellis, Ian O., Rakha, Emad A., Jackson, Andrew M., Spendlove, Ian, Ramage, Judith M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418069/ https://www.ncbi.nlm.nih.gov/pubmed/30474779 http://dx.doi.org/10.1007/s10549-018-5063-9

Ejemplares similares

Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival
por: Joseph, Chitra, et al.
Publicado: (2020)

Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2020)

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
por: Aleskandarany, Mohammed, et al.
Publicado: (2015)

The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer
por: El Ansari, Rokaya, et al.
Publicado: (2020)

Biological and clinical significance of PARP1 protein expression in breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy
por: Al-Subhi, Nouf, et al.
Publicado: (2018)

Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers
por: Ahmad, Dena A. J., et al.
Publicado: (2016)

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2021)

Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients
por: Mirza, Sameer, et al.
Publicado: (2013)

Phenotypic characterisation of breast cancer: the role of CDC42
por: Chrysanthou, Eleni, et al.
Publicado: (2017)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development
por: Aljohani, Abrar I., et al.
Publicado: (2022)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
por: Muftah, Abir A., et al.
Publicado: (2017)

Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients
por: Zhao, Xiangshan, et al.
Publicado: (2012)

Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers
por: Savva, Constantinos, et al.
Publicado: (2019)

The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
por: Althobiti, Maryam, et al.
Publicado: (2020)

The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

The intra-tumoural stroma in patients with breast cancer increases with age
por: Vangangelt, Kiki M. H., et al.
Publicado: (2019)

Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer
por: Althobiti, Maryam, et al.
Publicado: (2021)

Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer
por: Elsharawy, Khloud A., et al.
Publicado: (2020)

The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS)
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer
por: Kariri, Yousif, et al.
Publicado: (2022)

The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2020)

Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2019)

Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer
por: Green, Andrew R., et al.
Publicado: (2016)

Patterns of biomarker expression in patients treated with primary endocrine therapy – a unique insight using core needle biopsy tissue microarray
por: Parks, R. M., et al.
Publicado: (2020)

T-bet(+) lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer
por: Mori, Hitomi, et al.
Publicado: (2019)

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
por: Li, Kai, et al.
Publicado: (2020)

Connexin43 Hemichannel-Mediated Regulation of Connexin43
por: Li, Kai, et al.
Publicado: (2013)

Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival
por: Weigman, Victor J., et al.
Publicado: (2011)

Subcellular localization of anthracyclines in cultured rat cardiomyoblasts as possible predictors of cardiotoxicity
por: Studzian, Kazimierz, et al.
Publicado: (2015)

Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients
por: Mast, Mirjam E., et al.
Publicado: (2014)

Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients
por: Engstrøm, M. J., et al.
Publicado: (2013)

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
por: Gelbert, Lawrence M., et al.
Publicado: (2014)

Intrinsic subtypes in Ethiopian breast cancer patient
por: Desalegn, Zelalem, et al.
Publicado: (2022)

Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer
por: Verma, Rashmi, et al.
Publicado: (2020)

Identification of candidate mediators of chemoresponse in breast cancer through therapy-driven selection of somatic variants
por: Al Amri, Waleed S., et al.
Publicado: (2020)

Contrast enhanced mammography in breast cancer surveillance
por: Elder, Kenneth, et al.
Publicado: (2023)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0ai9hnh1k3l8gjaivq7kcadkar